|
|
|
Allos
Therapeutics, Inc. (NASDAQ: ALTH)
is a biopharmaceutical
company focused on developing and commercializing innovative small molecule
drugs for
the treatment of cancer. The Company’s product candidate,
pralatrexate, is a targeted antifolate designed to accumulate preferentially in cancer
cells. In March 2009, the Company submitted
a New Drug Application (NDA) to the U.S. Food
and Drug Administration (FDA) for approval to market pralatrexate for the
treatment of patients with relapsed or refractory peripheral T-cell lymphoma. In May 2009, the
FDA accepted the Company’s NDA for priority
review and established a Prescription Drug User Fee
Act date of September 24, 2009 for a decision regarding
approval of the NDA. In addition, pralatrexate is being evaluated in patients
with non-small cell lung cancer, bladder cancer and a
range of lymphoma sub-types. Allos currently retains exclusive worldwide rights
to pralatrexate for all indications.
Click
here to learn more about pralatrexate
|
|